Hyperfine Management
Management criteria checks 3/4
Hyperfine's CEO is Maria Degois-Sainz, appointed in Oct 2022, has a tenure of 3.58 years. total yearly compensation is $896.82K, comprised of 64.9% salary and 35.1% bonuses, including company stock and options. directly owns 0.04% of the company’s shares, worth $66.90K. The average tenure of the management team and the board of directors is 1.5 years and 4.4 years respectively.
Key information
Maria Degois-Sainz
Chief executive officer
US$896.8k
Total compensation
| CEO salary percentage | 64.92% |
| CEO tenure | 3.6yrs |
| CEO ownership | 0.04% |
| Management average tenure | 1.5yrs |
| Board average tenure | 4.4yrs |
Recent management updates
Recent updates
Narrative Update • Apr 30
HYPR: European Approvals And New Financing Will Support Future Upside Potential
Analysts have raised their price target on Hyperfine by $0.30, citing updated fair value assumptions of $1.60 per share that reflect adjusted expectations for revenue growth, profit margins, discount rate, and a higher future P/E multiple. What's in the News Received CE Marking and UK Conformity Assessment approval for the next generation Swoop portable MRI system and the latest Optive AI software, allowing commercialization across Europe and the UK.
Narrative Update • Apr 16
HYPR: European Approvals And Clinical Evidence Will Drive Future Upside
Analysts now set a $2.05 price target for Hyperfine, unchanged from before, reflecting updated views on discount rate, profit margin, and expected future P/E, without a shift in the overall valuation level. What's in the News Hyperfine received CE Marking and UKCA approval for its next generation Swoop system and latest Optive AI software, clearing the way for commercialization of its portable MRI technology across Europe and the UK and broadening its international reach in brain imaging (Product related announcement).Narrative Update • Apr 01
HYPR: Growing Clinical Evidence In Stroke And Outpatient Care Will Drive Upside
Analysts have lifted their Hyperfine price target from $1.65 to $2.05, citing updated assumptions around discount rates, revenue growth, profit margins and future P/E that adjust the stock's risk and earnings outlook in their models. What’s in the News Entered a new loan and security agreement with Horizon Technology Finance Corporation for a senior secured term loan facility of up to US$40 million, including an initial US$15 million draw and the option to access an additional US$25 million through December 31, 2027, with interest only payments through March 18, 2031 (Key Developments).Narrative Update • Mar 18
HYPR: Expanding Stroke And Outpatient Evidence Will Support Future Upside
Analysts have maintained their $1.65 price target for Hyperfine, citing largely unchanged assumptions for fair value, discount rate, revenue growth, profit margin, and future P/E as the basis for this view. What's in the News The largest data set to date for stroke detection with the Swoop system reported strong evidence supporting AI powered portable MRI for ischemic stroke detection in emergency and other clinical settings.Narrative Update • Mar 04
HYPR: Expanding Clinical Evidence And New Trials Will Support Future Upside
Analysts have kept their price target for Hyperfine steady at $1.65, with small tweaks to assumptions such as a slightly higher discount rate, modestly better projected profit margin, and a somewhat lower future P/E helping to support the unchanged view. What's in the News The largest stroke detection data set to date for the Swoop system was reported.Narrative Update • Feb 18
HYPR: India Approval And Clinical Data Will Support Future Upside Potential
Analysts have modestly revised their price target for Hyperfine to $1.30, reflecting updated assumptions around a slightly lower discount rate, marginally higher revenue growth and profit margin expectations, and a small adjustment to the projected future P/E multiple. What's in the News The largest stroke detection data set for the Swoop system was published in Stroke: Vascular and Interventional Neurology.Narrative Update • Feb 04
HYPR: Growing Clinical Evidence And New Approvals Will Support Upside
Analysts have kept their price target for Hyperfine unchanged at $1.65, reflecting only minor adjustments to underlying model inputs such as the discount rate, revenue growth, profit margin, and future P/E assumptions. What's in the News The largest-to-date stroke detection study with the Swoop system reported strong sensitivity and specificity for ischemic lesion detection, including very small strokes, with shorter scan times and improved brain image quality in emergency settings (Stroke: Vascular and Interventional Neurology).Narrative Update • Jan 21
HYPR: Expanded Clinical Use And New Regulatory Wins Will Drive Upside
Analysts have modestly adjusted their price target for Hyperfine to US$1.65, reflecting tweaks to key inputs such as a slightly lower discount rate, marginally softer revenue growth and profit margin assumptions, and a higher future P/E expectation. What's in the News Hyperfine enrolled the first patient in the Contrast PMR study, a prospective multi center trial evaluating contrast enhanced ultra low field portable MRI to support a potential future FDA submission to expand Swoop system use with gadolinium based contrast agents.Analysis Article • Jan 15
Revenues Tell The Story For Hyperfine, Inc. (NASDAQ:HYPR) As Its Stock Soars 34%
Hyperfine, Inc. ( NASDAQ:HYPR ) shareholders are no doubt pleased to see that the share price has bounced 34% in the...Narrative Update • Jan 06
HYPR: India Approval Will Support Future Upside Potential
Analysts have modestly adjusted their price target on Hyperfine, reflecting small tweaks to the discount rate, revenue growth and future P/E assumptions while keeping fair value steady at US$1.30. What's in the News Hyperfine received regulatory approval in India for its Swoop portable MRI system from the Central Drugs Standard Control Organization, allowing commercialization across the country through a distribution partnership with Radiosurgery Global Ltd.Narrative Update • Dec 18
HYPR: India Approval And New MRI Software Will Drive Strong Upside Potential
Analysts have raised their price target on Hyperfine from approximately $0.85 to $1.30 per share, citing stronger projected revenue growth, slightly improved profit margins, and a higher expected future P E multiple, despite a modest uptick in the assumed discount rate. What's in the News Hyperfine received regulatory approval from India's Central Drugs Standard Control Organization to commercialize its Swoop portable MRI system nationally, opening access to advanced brain imaging in a large, under-served market (Key Developments).Narrative Update • Dec 04
HYPR: Expanded Clinical Use And Subscription Platform Will Drive Future Upside
Analysts have maintained their price target for Hyperfine at 1.65 dollars, reflecting largely unchanged views on the company. Slight improvements in discount rate and profit margin estimates are offset by a marginally lower future earnings multiple.Narrative Update • Nov 20
HYPR: Expanding Clinical Applications Will Drive 2025 Revenue Acceleration
Narrative Update on Hyperfine: Analyst Price Target Revision Analysts have slightly reduced their price target for Hyperfine from $1.70 to $1.65, citing updated forecasts for revenue growth and profit margins as key factors behind the adjustment. What's in the News Management expects fourth quarter 2025 revenue to be approximately $5 to $6 million, which would represent sequential and year-over-year quarterly growth of 60% and 137%, respectively.Narrative Update • Nov 05
HYPR: International Approvals And Expanded Use Will Drive Upside Momentum
Narrative Update on Hyperfine Analyst Price Target Analysts have maintained their fair value estimate for Hyperfine at $1.70. They cite largely unchanged growth projections along with only small adjustments in profit margin and discount rate assumptions.Narrative Update • Oct 21
Analysts Lift Hyperfine Price Target Amid Positive Studies and Stronger Revenue Growth Forecast
Analysts have raised their price target for Hyperfine from $1.42 to $1.70. They cite higher projected revenue growth and a slightly lower discount rate as reasons for a more bullish outlook.Analysis Article • Oct 07
Hyperfine, Inc. (NASDAQ:HYPR) Looks Just Right With A 30% Price Jump
Despite an already strong run, Hyperfine, Inc. ( NASDAQ:HYPR ) shares have been powering on, with a gain of 30% in the...Narrative Update • Aug 29
FDA Clearances And Demographics Will Create Opportunity Despite Valuation Risks
The significant upward revision in Hyperfine’s consensus analyst price target is primarily driven by a notable increase in its forecasted Future P/E, with fair value rising from $1.19 to $1.42. What's in the News Hyperfine provided 2025 earnings guidance, expecting 10%–20% revenue growth over 2024.Narrative Update • Aug 15
FDA Clearances And Demographics Will Create Opportunity Despite Valuation Risks
With both Net Profit Margin and Future P/E essentially unchanged, analysts have maintained their consensus price target for Hyperfine at $1.19. What's in the News Hyperfine received FDA clearance for its next-generation portable MRI system powered by Optive AI software, delivering significant improvements in image quality, speed, and usability, targeting broader adoption across diverse care settings, including hospitals, neurology offices, and remote environments.Analysis Article • Jul 23
Market Participants Recognise Hyperfine, Inc.'s (NASDAQ:HYPR) Revenues Pushing Shares 46% Higher
Hyperfine, Inc. ( NASDAQ:HYPR ) shares have had a really impressive month, gaining 46% after a shaky period beforehand...Analysis Article • May 16
Here's Why Hyperfine (NASDAQ:HYPR) Must Use Its Cash Wisely
We can readily understand why investors are attracted to unprofitable companies. For example, although...
New Narrative • Apr 09
2025 Swoop Software Releases Will Boost Healthcare Imaging Adoption
Launching AI-powered software and expanding into neurology offices will likely enhance market penetration and diversify revenue streams.Analysis Article • Mar 22
What You Can Learn From Hyperfine, Inc.'s (NASDAQ:HYPR) P/S After Its 28% Share Price Crash
Hyperfine, Inc. ( NASDAQ:HYPR ) shares have had a horrible month, losing 28% after a relatively good period beforehand...Analysis Article • Feb 05
Hyperfine, Inc. (NASDAQ:HYPR) Looks Just Right With A 25% Price Jump
Hyperfine, Inc. ( NASDAQ:HYPR ) shares have continued their recent momentum with a 25% gain in the last month alone...Analysis Article • Nov 15
Analysts Are Updating Their Hyperfine, Inc. (NASDAQ:HYPR) Estimates After Its Third-Quarter Results
Shareholders might have noticed that Hyperfine, Inc. ( NASDAQ:HYPR ) filed its third-quarter result this time last...Seeking Alpha • Oct 06
Hyperfine appoints Maria Sainz as President, CEO
Hyperfine (NASDAQ:HYPR) has named medical device industry veteran Maria Sainz as President and CEO of Hyperfine, effective Oct. 24, 2022. Scott Huennekens, who currently serves as interim President and CEO, will stay on as Executive Chairperson of the Board. HYPR -5.79% premarket to $1.14.CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Dec 31 2025 | US$897k | US$582k | -US$36m |
| Sep 30 2025 | n/a | n/a | -US$40m |
| Jun 30 2025 | n/a | n/a | -US$39m |
| Mar 31 2025 | n/a | n/a | -US$40m |
| Dec 31 2024 | US$2m | US$568k | -US$41m |
| Sep 30 2024 | n/a | n/a | -US$41m |
| Jun 30 2024 | n/a | n/a | -US$41m |
| Mar 31 2024 | n/a | n/a | -US$42m |
| Dec 31 2023 | US$847k | US$550k | -US$44m |
| Sep 30 2023 | n/a | n/a | -US$47m |
| Jun 30 2023 | n/a | n/a | -US$49m |
| Mar 31 2023 | n/a | n/a | -US$62m |
| Dec 31 2022 | US$4m | US$95k | -US$73m |
| Sep 30 2022 | n/a | n/a | -US$86m |
| Jun 30 2022 | n/a | n/a | -US$89m |
| Mar 31 2022 | n/a | n/a | -US$81m |
| Dec 31 2021 | US$182k | n/a | -US$65m |
Compensation vs Market: Maria's total compensation ($USD896.82K) is below average for companies of similar size in the US market ($USD1.59M).
Compensation vs Earnings: Maria's compensation has been consistent with company performance over the past year.
CEO
Maria Degois-Sainz (59 yo)
3.6yrs
Tenure
US$896,817
Compensation
Ms. Maria Degois-Sainz is Independent Director of Pulse Biosciences, Inc. from January 9, 2026. Ms. Degois-Sainz is Chair of the Board of Onera Technologies B.V. from January 2025. Ms. Degois-Sainz serves...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO, President & Director | 3.6yrs | US$896.82k | 0.040% $ 66.9k | |
| Founder & Vice Chairman | 12.3yrs | US$50.00k | 16.55% $ 27.5m | |
| Chief Administrative Officer | 3.3yrs | US$799.63k | 0.052% $ 85.9k | |
| Chief Operating Officer | 2.8yrs | US$799.63k | 0.13% $ 219.1k | |
| Vice President of Technology | 1.2yrs | no data | no data | |
| Senior Vice President of Office Strategy and Partnerships | 1.3yrs | no data | no data | |
| Chief Medical Officer | 1.6yrs | no data | no data | |
| Senior Vice President of Hospital Business | 1.3yrs | no data | no data | |
| Chief Regulatory & Quality Officer | less than a year | no data | no data |
1.5yrs
Average Tenure
55yo
Average Age
Experienced Management: HYPR's management team is not considered experienced ( 1.5 years average tenure), which suggests a new team.
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO, President & Director | 4.4yrs | US$896.82k | 0.040% $ 66.9k | |
| Founder & Vice Chairman | 12.3yrs | US$50.00k | 16.55% $ 27.5m | |
| Independent Director | 4.8yrs | US$129.29k | 0.021% $ 34.6k | |
| Independent Director | 4.4yrs | US$129.63k | 0.020% $ 33.1k | |
| Independent Chairperson | 4.4yrs | US$197.37k | 0.020% $ 33.1k | |
| Member of Advisory Board | no data | no data | no data | |
| Member of Medical Advisory Board | no data | no data | no data | |
| Member of Medical Advisory Board | no data | no data | no data | |
| Member of Medical Advisory Board | no data | no data | no data | |
| Member of Medical Advisory Board | no data | no data | no data | |
| Member of Medical Advisory Board | no data | no data | no data | |
| Member of Medical Advisory Board | no data | no data | no data |
4.4yrs
Average Tenure
68yo
Average Age
Experienced Board: HYPR's board of directors are considered experienced (4.4 years average tenure).
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/05/11 09:57 |
| End of Day Share Price | 2026/05/11 00:00 |
| Earnings | 2025/12/31 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Hyperfine, Inc. is covered by 4 analysts. 3 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Yuan Zhi | B. Riley Securities, Inc. |
| Marie Thibault | BTIG |
| Vijay Kumar | Evercore ISI |